Miles Capital Inc. lessened its stake in Pfizer Inc. (NYSE:PFE) by 10.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,446 shares of the biopharmaceutical company’s stock after selling 1,836 shares during the quarter. Miles Capital Inc.’s holdings in Pfizer were worth $644,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Integrated Wealth Concepts LLC lifted its holdings in Pfizer by 14.2% in the second quarter. Integrated Wealth Concepts LLC now owns 68,060 shares of the biopharmaceutical company’s stock valued at $2,840,000 after buying an additional 8,445 shares during the period. Halsey Associates Inc. CT lifted its holdings in Pfizer by 73.8% during the third quarter. Halsey Associates Inc. CT now owns 44,316 shares of the biopharmaceutical company’s stock worth $1,592,000 after acquiring an additional 18,822 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in Pfizer by 999.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 82,455 shares of the biopharmaceutical company’s stock worth $3,231,000 after acquiring an additional 74,955 shares in the last quarter. Whitnell & Co. lifted its holdings in Pfizer by 390.0% during the third quarter. Whitnell & Co. now owns 50,507 shares of the biopharmaceutical company’s stock worth $1,815,000 after acquiring an additional 40,200 shares in the last quarter. Finally, IHT Wealth Management LLC grew its stake in Pfizer by 20.5% in the third quarter. IHT Wealth Management LLC now owns 72,126 shares of the biopharmaceutical company’s stock valued at $2,595,000 after acquiring an additional 12,291 shares during the period. 70.22% of the stock is owned by institutional investors.
Several brokerages have issued reports on PFE. Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target on the stock in a research report on Tuesday, October 1st. Royal Bank of Canada started coverage on Pfizer in a research note on Monday, January 6th. They set an “outperform” rating and a $46.00 target price for the company. ValuEngine upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Credit Suisse Group reaffirmed a “hold” rating and issued a $41.30 price objective on shares of Pfizer in a research report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Pfizer in a research note on Tuesday, October 29th. Nine investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $43.41.
Shares of PFE stock traded down $0.03 during trading on Tuesday, reaching $40.48. 5,626,906 shares of the company’s stock were exchanged, compared to its average volume of 14,027,554. Pfizer Inc. has a twelve month low of $33.97 and a twelve month high of $44.56. The firm’s fifty day moving average price is $39.10 and its 200-day moving average price is $38.11. The company has a quick ratio of 0.68, a current ratio of 0.90 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $224.19 billion, a PE ratio of 14.15, a PEG ratio of 4.24 and a beta of 0.65.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.13. The business had revenue of $12.68 billion during the quarter, compared to the consensus estimate of $12.37 billion. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The company’s quarterly revenue was down 4.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.78 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 31st will be issued a dividend of $0.38 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, January 30th. This represents a $1.52 annualized dividend and a dividend yield of 3.76%. Pfizer’s payout ratio is presently 48.00%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Recommended Story: What is the market perform rating?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.